Ask AI
ProCE Banner Series

mTNBC Practice Readiness: Applying Current Standards and Interpreting Emerging First-line TROP2 ADC Evidence for Immunotherapy-Ineligible Patients

Join this webinar with contemporary expert insights on applying current standards and interpreting emerging data for first-line use of TROP2 ADC agents in patients with metastatic TNBC not eligible for immunotherapy.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This activity is intended for oncologists and the multidisciplinary team caring for patients with metastatic triple-negative breast cancer, including advanced practice providers, nurses and nurse navigators, patient navigators, physician associates, pharmacists, and eye care specialists (ophthalmologists and optometrists).

All Events

mTNBC Practice Readiness: Applying Current Standards and Interpreting Emerging First-line TROP2 ADC Evidence for Immunotherapy-Ineligible Patients

Upcoming Events

September

16

2026

1:00 PM - 2:00 PM Central Time (CT)

Virtual

Topics

Breast Cancers

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
Improve learners’ ability to apply current standards of care and interpret current and emerging first-line TROP2 ADC evidence in immunotherapy-ineligible metastatic triple-negative breast cancer, with practice-ready strategies for treatment selection and sequencing, proactive adverse-event prevention and management, patient counseling, and coordinated oncology–eye care to preserve treatment continuity and quality of life.

Target Audience
This activity is intended for oncologists and the multidisciplinary team caring for patients with metastatic triple-negative breast cancer, including advanced practice providers, nurses and nurse navigators, patient navigators, physician associates, pharmacists, and eye care specialists (ophthalmologists and optometrists).

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Interpret current and emerging clinical evidence for TROP2 ADC–based strategies in immunotherapy-ineligible mTNBC, including implications for first-line and later-line treatment planning

  • Individualize treatment selection and sequencing for patients with mTNBC who are not candidates for immunotherapy, integrating prior therapy exposure, disease burden, comorbidities, toxicity risk, and patient preferences

  • Implement multidisciplinary monitoring, toxicity-prevention, and AE-management pathways for patients receiving TROP2-directed therapy, including timely triage and oncology–eye care coordination when clinically indicated

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-26-361-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

American Board of Internal Medicine Maintenance of Certification

Title: A blue and black sign with white textDescription automatically generated

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABIM MOC credit.

For ABIM MOC points, your information will be shared with the ABIM through Decera Clinical Education’s Joint Accreditation Program and Activity Reporting System (JAPARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

By sharing your Diplomate Board ID # and DOB, you are giving Decera Clinical Education permission to use this information/data to report your participation to these Boards via the Joint Accreditation Program and Activity Reporting System (JA-PARS).

IPCE Credit Designation

https://omni-channel-2022-assets-production.s3.amazonaws.com/editorupload/657115052be04.jpg

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191